This article is more than 5 years old. Information may no longer be current.
MiSight approval leads November ophthalmology news
Two FDA actions topped ophthalmology news in November, with an approval for the MiSight contact lens and an orphan drug designation for ProQR’s retinitis pigmentosa treatment.
Here are the top five most-read articles on Healio/OSN last month:
FDA approves MiSight contact lens to slow myopia progression in children
The MiSight contact lens (CooperVision) is a disposable, soft lens that is limited for one-time use and is not for wearing overnight. Read more.
ProQR’s retinitis pigmentosa treatment gets orphan drug designation
QR-1123, a first-in-class investigational antisense oligonucleotide for the treatment of vision loss associated with autosomal dominant retinitis pigmentosa, received an orphan drug designation from the FDA. Read more.
Light Adjustable Lens a disruptive technology in cataract surgery
Since its commercial rollout in July, the Light Adjustable Lens has been implanted in 18 sites across the country, offering surgeons simplified preoperative messaging and decision-making and delivering better vision for patients. Read more.
EyeGate’s Ocular Bandage Gel eye drop meets endpoint
EyeGate Pharmaceuticals’ Ocular Bandage Gel eye drop improved corneal re-epithelialization better than a bandage contact lens in a pivotal PRK study, thus achieving the study’s primary endpoint. Read more.
Omidria lessens need for fentanyl during cataract surgery
Significantly fewer patients undergoing cataract surgery who received intracameral Omidria experienced severe pain or required intraoperative fentanyl than did patients who received epinephrine. Read more.